According to Royalty Pharma latest financial reports the total liabilities of RPRX is $6.30B, an decrease of -13.59% to 2022. At the end of 2022 company had $7.29B total liabilities. This figure represents the company's financial obligations and debts, including loans, accounts payable, and other liabilities that Royalty Pharma is responsible for during its operational activities.
Year | Total liabilities | Change |
---|---|---|
2023 | $6.30B | -13.59% |
2022 | $7.29B | 0.29% |
2021 | $7.27B | 18.66% |
2020 | $6.12B | -2.92% |
2019 | $6.31B | -3.30% |
2018 | $6.52B | - |